Latest News, Announcements, and Press Releases

REDWOOD CITY, Calif. , April 05, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that Jim Lalonde , Ph.D., Senior Vice President of Research and Development, will resign effective May 31, 2019 to pursue…

REDWOOD CITY, Calif. , March 05, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that management will participate in two upcoming investment conferences: Cowen and Company 39 th Annual Health Care Conference on Tuesday,…

2018 revenues of $61 million include a 50% increase in R&D revenue  Introduces 2019 financial guidance Conference call begins at 4:30 pm Eastern time today Accompanying slide presentation available on Investor section of company website REDWOOD CITY, Calif. , Feb.

REDWOOD CITY, Calif. , Feb. 25, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the appointment of Laurie Heilmann to Senior Vice President of Business Development and Marketing. Heilmann brings to Codexis more than…

REDWOOD CITY, Calif. , Feb. 19, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces that it will report 2018 fourth quarter and full year financial results after market close on Tuesday, February 26, 2019…

REDWOOD CITY, Calif. , Feb. 14, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (Nasdaq: CDXS), a leading protein engineering company, announces that Nestlé Health Science has exercised its option to obtain an exclusive license for the global development and commercialization of…

REDWOOD CITY, Calif. , Feb. 06, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS) announces a multi-year, exclusive supply agreement with KYORIN Pharmaceutical Co., Ltd. for the supply of a proprietary enzyme to be used in the manufacture of vibegron,…

REDWOOD CITY, Calif. , Feb. 04, 2019 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces the signing of a new agreement with Merck, through a subsidiary. Under the terms of the agreement, Codexis will install…

Total revenues increase 70% to $16.9 million driven by higher product revenue and R&D revenue across an increased number of customers Conference call begins at 4:30 p.m. Eastern time today REDWOOD CITY, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) —…

CDX-6114 meets safety and tolerability endpoints REDWOOD CITY, Calif. , Nov. 08, 2018 (GLOBE NEWSWIRE) — Codexis, Inc. (NASDAQ: CDXS), a leading protein engineering company, announces top-line results from its Phase 1a single ascending-dose study in healthy volunteers with CDX-6114,…